Site-specific proteolysis of cyclooxygenase-2: A putative step in inflammatory prostaglandin E2 biosynthesis

Journal of Cellular Biochemistry

Volumn 101, Issue 2, 2007, Pages 425-441

  Mancini, Arturo ^a   Jovanovic, Dragan V ^a   He, Qing W ^a   Di Battista, John A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cyclooxygenase 2; Post translational regulation; Primary human cells; Proinflammatory cytokines; Proteolysis; Proteomics

Indexed keywords

CALPAIN; CATHEPSIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROTEINASE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME STABILITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEINASE INHIBITION; REGULATORY MECHANISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, JUVENILE RHEUMATOID; CELLS, CULTURED; CYCLOOXYGENASE 2; CYSTEINE PROTEINASE INHIBITORS; DINOPROSTONE; FIBROBLASTS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; MACROPHAGES; PEPTIDE FRAGMENTS; SYNOVIAL MEMBRANE;

EID: 34247895500     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21191     Document Type: Article

References (40)

1. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. 1999a. Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: Distinct targeting in the signaling pathways. Arthritis Rheum 42:710-718.
2. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. 1999b. Differential effects of IL-8, LIF (pro-inflammatory) and IL-11 (anti-inflammatory) on TNF-alpha-induced PGE(2)release and on signalling pathways in human OA synovial fibroblasts. Cytokine 11:1020-1030.
3. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. 1986. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29:1039-1049.
4. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. 1994. Structure of the human cyclo-oxygenase-2 gene. Biochem J 302:723-727.
5. Banik NL, Matzelle D, Terry E, Gantt-Wilford G, Hogan EL. 2000. Inhibition of proteolysis by a cyclooxygenase inhibitor, indomethacin. Neurochem Res 25:1509-1515.
6. Dean JL, Brook M, Clark AR, Saklatvala J. 1999. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 274:264-269.
7. Di Battista JA, Zhang M, Martel-Pelletier J, Fernandes J, Alaaeddine N, Pelletier JP. 1999. Enhancement of phosphorylation and transcriptional activity of the glucocorticoid receptor in human synovial fibroblasts by nimesulide, a preferential cyclooxygenase 2 inhibitor. Arthritis Rheum 42:157-166.
8. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols W, Jessing KW, Zavitz KH, Koo EH, Golde TE. 2003. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112:440-449.
9. Espel E. 2005. The role of the AU-rich elements of mRNAs in controlling translation. Semin Cell Dev Biol 16:59-67.
10. Faour WH, He Y, He QW, de Ladurantaye M, Quintero M, Mancini A, Di Battista JA. 2001. Prostaglandin E(2) regulates the level and stability of cyclooxygenase-2 mRNA through activation of p38 mitogen-activated protein kinase in interleukin-1 beta-treated human synovial fibroblasts. J Biol Chem 276:31720-31731.
11. Faour WH, Mancini A, He QW, Di Battista JA. 2003. T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: Role of distal sequences in the 3′-untranslated region of COX-2 mRNA. J Biol Chem 278:26897-26907.
12. Franco SJ, Huttenlocher A. 2005. Regulating cell migration: Calpains make the cut. J Cell Sci 118:3829-3838.
13. Funk CD. 2001. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 294:1871-1875.
14. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K. 1995. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J 305:479-484.
15. Guo Q, Kulmacz RJ. 2000. Distinct influences of carboxyl terminal segment structure on function in the two isoforms of prostaglandin H synthase. Arch Biochem Biophys 384:269-279.
16. Harris J, Mason DE, Li J, Burdick KW, Backes BJ, Chen T, Shipway A, Van Heeke G, Gough L, Ghaemmaghami A, Shakib F, Debaene F, Winssinger N. 2004. Activity profile of dust mite allergen extract using substrate libraries and functional proteomic microarrays. Chem Biol 11:1361-1372.
17. Hawk E, Lubet R, Limburg P. 1999. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86:2551-2563.
18. Hiwasa T, Sanada T, Sakiyama S. 1990. Cysteine proteinase inhibitors and rasgene products share the same biological activities including tranforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. Carcinogenesis 11:75-80.
19. Huang X, Miller M. 1991. A time-efficient, linear-space local similarity algorithm. Adv Appl Math 12:337-357.
20. Hwang D. 2001. Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through toll-like receptor 4-derived signaling pathways. FASEB J 15:2556-2564.
21. Kulmacz RJ, van der Donk WA, Tsai AL. 2003. Comparison of the properties of prostaglandin H synthase-1 and -2. Prog Lipid Res 42:377-404.
22. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC. 1996. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384:644-648.
23. Lipsky PE. 1999. Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop 28:8-12.
24. McGowan EB, Becker E, Detwiler TC. 1989. Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem Biophys Res Commun 158:432-435.
25. Miller C, Zhang M, He Y, Zhao J, Pelletier JP, Martel-Pelletier J, Di Battista JA. 1998. Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. J Cell Biochem 69:392-413.
26. Milligan SA, Owens MW, Grisham MB. 1996. Inhibition of IkappaB-alpha and IkappaB-beta proteolysis by calpain inhibitor I blocks nitric oxide synthesis. Arch Biochem Biophys 335:388-395.
27. Morita I. 2002. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69:169-175.
28. Otto JC, Smith WL. 1994. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J Biol Chem 269:19868-19875.
29. Picot D, Loll PJ, Garavito RM. 1994. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1, Nature 367:243-249.
30. Rogge CE, Liu W, Wu G, Wang LH, Kulmacz RJ, Tsai AL. 2004. Identification of Tyr504 as an alternative tyrosyl radical site in human prostaglandin H synthase-2. Biochemistry 43:1560-1568.
31. Shevchenko A, Wilm M, Vorm O, Mann M. 1996. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850-858.
32. Smith WL, DeWitt DL, Garavito RM. 2000. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 69:145-182.
33. Spencer AG, Woods JW, Arakawa T, Singer II, Smith WL. 1998. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 273:9886-9893.
34. Spencer AG, Thuresson E, Otto JC, Song I, Smith T, DeWitt DL, Garavito RM, Smith WL. 1999. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J Biol Chem 274:32936-32942.
35. Storer AC, Ménard R. 1996. Recent insights into cysteine protease specificity: Lessons for drug design. Perspect Drug Discovery Des 6:33-46.
36. Tamai M, Matsumoto K, Omura S, Koyama I, Ozawa Y, Kanada K. 1986. In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J Pharmacobiodyn 8:672-677.
37. Tanabe T, Tohnai N. 2002. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69:95-114.
38. Wechter WJ. 1994. Drug chirality: On the mechanism of R-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. J Clin Pharmacol 34:1036-1042.
39. Wun T, McKnight H, Tuscano JM. 2004. Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma. Leuk Res 28:179-190.
40. Zaric J, Ruegg C. 2005. Integrin-mediated adhesion and soluble ligand binding stabilize COX-2 protein levels in endothelial cells by inducing expression and preventing degradation. J Biol Chem 280:1077-1085.